| [Objective]There has been several AIDS Genome-wide association studies which discovered many variants related to disease progression. To our knowledge, they have not been replicated in Asian population. We attempted to confirm these finding in Chinese population and studied the association between the classic AIDS restricted variants and disease progression as well as virological suppression after HAART therapy.[Methods]We recruited1098HIV infected subjects from4study cohort. We define Rate of CD4decline as phenotype of the disease progression study and time to virological control (VL<400/mL)/suppression (VL<50/mL) as phenotype of treatment response study.18SNPs of GWAS study and classic variants were selected. Kruskal Wallis Test and Pearson Chi-Square test were used. Significant variants in the first phase were replicated in a LTNP cohort.[Results]3SNPs were excluded which failed in Hardy-Weinberg test. In the disease progression study (n=376), rs9264942, rs13199524and rs12198173from GWAS showed statistically significant association with the rate of CD4decline, which were confirmed in the LTNP cohort. rs2395029from CHAVI study showed significant different frequency between reference population and LTNP cohort. None of the classic AIDS restricted variants showed statistically significant association with the rate of CD4decline. In treatment response study, baseline VL is an independent influence factor of time to virological control/suppression. After correcting the influence of baseline VL, None of the classic AIDS restricted variants showed statistically significant association with time to virological control/suppression in Chinese population.[Conclusions] Our study for the first time replicated the major variants from GWAS in Chinese population which shows the central role of MHC region in Chromosome6in the control of HIV viral replication and disease progress. Baseline VL, as an independent influence factor of time to virological control/suppression, implies more potent HAART regime in case of resistance in high baseline VL patients. |
